Breakthrough in Cancer Precision Therapy: Identifying Patients Who Benefit from Bexmarilimab
A new study unveils how bexmarilimab activates the immune system against cancer and introduces a gene signature for selective patient treatment, advancing personalized immunotherapy.
Researchers at the University of Turku in Finland have made significant progress in improving targeted cancer treatments with their latest study on bexmarilimab, an immunotherapy antibody. The study investigates the specific conditions under which bexmarilimab can effectively activate the immune system to fight cancer. Notably, the drug has the potential to 'reawaken' macrophages—key immune cells involved in the body's defense—particularly when tumors exist within an immunologically silent microenvironment. Furthermore, the research reveals that bexmarilimab can stimulate B cell–mediated immune responses in healthy tissue neighboring the tumor, regardless of the tumor’s sensitivity to therapy, suggesting immunological effects beyond the tumor itself.
A major advancement from this study is the development of a gene signature—analyzing the expression of five specific genes—that predicts which patients are most likely to respond positively to bexmarilimab treatment. This predictor tool holds promise for more precise patient selection, potentially enhancing treatment success rates. Researchers validated these findings using patient-derived tissue samples that closely mimic actual tumor-immune interactions, aligning with clinical trial outcomes.
Developed in Finland, bexmarilimab has shown encouraging results across various solid tumors. The insights gained from this study aim to optimize its use, tailoring therapies based on tumor microenvironment characteristics. "Understanding tumor biology better allows us to personalize immunotherapy, supporting the approach with gene signatures that could guide clinical decisions," said Dr. Maija Hollmén.
The discovery emphasizes the importance of the tumor microenvironment in immunotherapy efficacy and paves the way for expanded, more targeted treatments in the future.
For more details, see the study by Jenna H Rannikko et al. in the Journal for ImmunoTherapy of Cancer (2025). Source: https://medicalxpress.com/news/2025-05-advances-cancer-precision-therapies-patients.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Brain Network Activity Could Predict Future Drinking Habits in Adolescents
New study reveals that brain network activity in adolescents may serve as a predictor for future alcohol consumption, offering promising insights for early intervention in preventing alcohol use disorder.
Impact of Food Additives During Pregnancy on Offspring Gut Health and Inflammation Risk
Maternal consumption of common food emulsifiers can alter offspring gut microbiota, increasing the risk of inflammatory diseases and obesity later in life, according to recent mouse studies.
Frontline Nurses Highlight Staffing Challenges, Language Barriers, and Profit-Driven Care Models
A new study highlights critical nurse-reported barriers to high-quality, equitable hospital care, emphasizing staffing, language access, and systemic profit motives as key challenges.
Potential Risks of Taurine: Its Role in Promoting Leukemia Growth
Recent research uncovers the role of taurine in promoting leukemia growth by supporting cancer cell metabolism, highlighting the need for caution with taurine supplementation in at-risk individuals.